Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy.

about

Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy.

Item

http://www.wikidata.org/entity/Q47160950

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy.

@en

Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy.

@nl

type

Item

label

Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy.

@en

Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy.

@nl

prefLabel

Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy.

@en

Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy.

@nl

P1476

Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy.

@en

P2093

David J Russell

http://www.w3.org/2001/XMLSchema#string

Lilly H Wagner

http://www.w3.org/2001/XMLSchema#string

Stuart R Seiff

http://www.w3.org/2001/XMLSchema#string

P2860

A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts.

Teprotumumab for Thyroid-Associated Ophthalmopathy.

Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.

Methotrexate for the treatment of thyroid eye disease.

Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity.

Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease.

Interleukin-6 stimulates thyrotropin receptor expression in human orbital preadipocyte fibroblasts from patients with Graves' ophthalmopathy.

Clinical Response to Tocilizumab in Severe Thyroid Eye Disease.

P304

146-148

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1016/J.AJOC.2017.07.001

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29260102

http://www.w3.org/2001/XMLSchema#string

P932

5722155

http://www.w3.org/2001/XMLSchema#string